Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study - PubMed
5 hours ago
- #real-world study
- #multiple myeloma
- #bispecific antibodies
- Study compares elranatamab and teclistamab in relapsed/refractory multiple myeloma.
- No significant difference in median time to next treatment (11.0 vs 12.3 months).
- 3-year overall survival rates were similar (58.8% vs 59.7%).
- Teclistamab showed longer time to next treatment in patients with baseline thrombocytopenia or >5 prior treatments.
- Grade ≥3 neutropenia more frequent with teclistamab (84.6% vs 74.5%).
- Cytokine release syndrome more common with elranatamab (45.2% vs 27.1%).
- Similar rates of neurotoxicity syndrome and infections between both drugs.
- Findings support individualized treatment selection based on toxicity profiles.